Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.)
2006

Comparing Two Interferon Treatments for Melanoma

Sample size: 169 publication Evidence: moderate

Author Information

Author(s): Chiarion-Sileni Vanna, Del Bianco Paola, Romanini Antonella, Guida Michele, Paccagnella Adriano, Dalla Palma Maurizio, Naglieri Emanuele, Ridolfi Ruggero, Silvestri Barbara, Michiara Maria, De Salvo Gian Luca

Primary Institution: Department of Medical Oncology, University Hospital, Padua, Italy

Hypothesis

Can a more intense but shorter interferon treatment improve survival for stage III melanoma patients without increasing toxicity?

Conclusion

The study found that four cycles of intravenous high-dose interferon can be safely delivered with an increase in the median dose intensity.

Supporting Evidence

  • The most common toxicities were flu-like and gastrointestinal symptoms.
  • Leukopenia was more frequent in the DD/DI arm than in the HDI arm (24% vs 9%).
  • The median actual dose intensity delivered in the DD/DI arm was significantly higher than that in the HDI arm.

Takeaway

Doctors wanted to see if giving a stronger dose of medicine for a shorter time would help people with skin cancer without making them feel worse. It looks like it worked better than the usual way.

Methodology

Patients were randomized to receive either a more intense intravenous interferon treatment or a standard treatment, and toxicity was recorded and graded.

Limitations

The study only reports on the first 169 patients and does not provide long-term efficacy results.

Participant Demographics

101 males and 65 females, mean age 49.1 years.

Statistical Information

P-Value

0.0074

Confidence Interval

95% confidence interval: 7.3–8.9

Statistical Significance

p = 0.0074

Digital Object Identifier (DOI)

10.1186/1471-2407-6-44

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication